The primary end point of improved progression-free survival was met in the phase 3 DESTINY-Breast02 trial when patients with HER2-positive unresectable and/or metastatic breast cancer were given trastuzumab deruxtecan vs physician’s choice of therapy.
Results from the phase 2 PEMMELA trial revealed positive treatment benefits in patients with malignant pleural mesothelioma who were given pembrolizumab plus lenvatinib.
Valentina Boni, MD, PhD, spoke about numerous trials in the breast cancer space presented at 2022 ASCO.
The phase 3 JAVELIN Lung did not produce statistically significant overall or progression-free survival benefit with avelumab for non–small cell lung cancer.
Ociperlimab plus tislelizumab showed promising antitumor activity in patients with treatment-naïve, metastatic, PD-L1–positive non–small cell lung cancer who were treated on the phase 1 AdvanTig-105 trial.
Tanios S. Bekaii-Saab, MD, discussed how data from clinical trials examining different targeted strategies in colorectal cancer will transform the way in which patients with this malignancy are seen and treated.
Results from the phase 3 RATIONALE-303 trial presented at 2022 WCLC showed an overall survival benefit when patients with non–small cell lung cancer were treated with second- or third-line tislelizumab compared with docetaxel.
Ian D. Davis, MBBS, PhD, spoke about the subgroup analysis of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.
Results from a phase 1b trial showed efficacy potential of sotorasib plus SHP2 inhibitor RMC-4630 for patients with pretreated or KRAS G12C inhibitor–naïve non–small cell lung cancer.
Follow-up to the phase 2 NAVIGATE and phase 1 LOXO-TRK-14001 trials showed durable responses and extended survival in patients with NTRK fusion–positive lung cancer who were treated with larotrectinib.
Regular approval has been granted to capmatinib for the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation.
At ASCO 2022, Roy S. Herbst, MD, PhD, reviews a substudy of the phase 2 Lung-MAP trial which investigates ramucirumab plus pembrolizumab for patients with advanced non–small cell lung cancer who demonstrated resistance to previous immunotherapy.
Adults with previously treated unresectable or metastatic non–small cell lung cancer whose tumors harbor HER2 mutations may now be treated with fam-trastuzumab deruxtecan-nxki.
At 2022 ASCO, Tanios S. Bekaii-Saab, MD, talks about how data from the ongoing MOUNTAINEER trial investigating trastuzumab plus tucatinib in HER2-positive metastatic colorectal cancer and other similar trials may impact the standard of care going forward.
Results from cohort C of the phase 2 VISION trial showed continued efficacy when tepotinib was given to patients with non–small cell lung cancer harboring MET exon 14 skipping alterations.
Elacestrant was granted priority review by the FDA for the treatment of estrogen receptor–positive, HER2-negative metastatic breast cancer.
Rafael Fonseca, MD, discusses use of elranatamab in patients with relapsed/refractory multiple myeloma and ongoing research into bispecific antibodies.
Experts indicated that 77% of women with lung cancer who were surveyed reported having moderate to severe sexual dysfunction.
The phase 3 RATIONALE 301 trial examining first-line tislelizumab vs sorafenib in unresectable hepatocellular carcinoma met the primary end point of noninferior overall survival.
Patients with advanced PD-L1–positive non–small cell lung cancer and squamous histology who were treated with sitravatinib plus tiselizumab had promising antitumor activity.
Paul G. Richardson, MD, looks at MRD data from the DETERMINATION study for its potential to guide treatment selection in newly diagnosed multiple myeloma.
Juan Pablo Alderuccio, MD, spoke with CancerNetwork® about a review article on the treatment of marginal zone lymphoma published in the journal ONCOLOGY®.
TROPION-Lung02 trial provides evidence of datopotamab deruxtecan and pembrolizumab efficacy in patients with advanced/metastatic non–small cell lung cancer and no actionable genomic alterations.
Overall survival, the primary end point of the phase 3 FRESCO-2 trial, was met when patients were given fruquintinib vs placebo for advanced refractory metastatic colorectal cancer.
Durvalumab plus tremelimumab in the first-line setting yielded improved overall survival vs chemotherapy in patients with metastatic non–small cell lung cancer.
At the 2022 WCLC, Brandon Sheffield, MD, presented data demonstrating the advantage of next-generation sequencing over other biomarker testing strategies in patients with non–small cell lung cancer.
After approximately 3.5 years of follow-up, patients with treatment-naive extensive-stage small cell lung cancer continued to derive survival benefit from pembrolizumab and etoposide.
Patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations experienced a survival benefit following treatment with tremelimumab plus durvalumab and chemotherapy in the first line.
Data from the phase 2 UCLA/TRIO-US L-07 trial presented at 2022 WCLC revealed that efficacy with talazoparib plus temozolomide improves upon historical controls in patients with extensive-stage small cell lung cancer.
Response rates with temozolomide plus nivolumab in extensive-stage small cell lung cancer show promise.
